Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1902 participants.

Also called NCT02593149

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,902 participants (enrolled count) (from the registry)
Sponsor
Pursuit Vascular, Inc. (from the registry)
Registry
  • NCT NCT02593149
Main results
  • Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection Journal of the American Society of Nephrology : JASN, 2018-04 DOI, PubMed 29472415, PMC5875956 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02593149. Randomized; no masking; primary purpose treatment. Start 2015-11 (actual); primary completion 2016-11 (actual). Results posted on 2019-02-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
Condition
End Stage Renal Disease (ESRD)
Intervention (Device)
ClearGuard HD End Cap
Lead sponsor
Pursuit Vascular, Inc. (class: industry)
Collaborator
Davita Clinical Research (class: industry)

Record details

Record id
cardio:ct-nct02593149
Content hash
df48edfd19dcae1da475b177fa4fa22e6b446db089e6df22f2e98eca52e6a1fa